Andrew D. Jones - Feb 15, 2023 Form 4 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Role
CFO
Signature
/s/ Andrew D. Jones
Stock symbol
NBY
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 04:30 PM
Previous filing
Dec 6, 2021
Next filing
Sep 3, 2024

Andrew D. Jones is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Remarks:

The reporting person departed from his position at NovaBay Pharmaceuticals, Inc., effective February 15, 2023. As a result, the reporting person is no longer subject to Section 16 in connection with his transactions in the equity securities of NovaBay Pharmaceuticals, Inc. and therefore will no longer report any such transactions on Form 4 or Form 5.